Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: A randomized, placebo-controlled study

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1944-1950

  Kim, Sun H ^a   Liu, Alice ^a   Ariel, Danit ^a   Abbasi, Fahim ^a   Lamendola, Cindy ^a   Grove, Kaylene ^a   Tomasso, Vanessa ^a   Ochoa, Hector ^a   Reaven, Gerald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PLACEBO; SALSALATE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ENDOCRINE PANCREAS FUNCTION TEST; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE INFUSION TEST; GLUCOSE TOLERANCE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SUPPRESSION TEST; INULIN CLEARANCE; MALE; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; BLOOD; DIET RESTRICTION; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; SECRETION (PROCESS);

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SALICYLATES; SINGLE-BLIND METHOD; TRIGLYCERIDES;

EID: 84903534630     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2977     Document Type: Article

References (26)

1. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901;1:760-762
2. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677 (Pubitemid 32807849)
3. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793-1801 (Pubitemid 44033299)
4. Möhlig M, Freudenberg M, Bobbert T, et al. Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. J Clin Endocrinol Metab 2006;91:964-967 (Pubitemid 43357766)
5. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-294 (Pubitemid 351213338)
6. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract 2012;18:826-833
7. Fernández-Real JM, López-Bermejo A, Ropero AB, et al. Salicylates increase insulin secretion in healthy obese subjects. J Clin Endocrinol Metab 2008;93:2523-2530 (Pubitemid 352008516)
8. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009;52:385-393
9. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013;56:714-723
10. Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab 1983;57:1102-1106 (Pubitemid 14209403)
11. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhäusl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 1985;28:671-676 (Pubitemid 16226405)
12. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
13. DeFronzo RA, Matsuda M. Reduced time points to calculate the composite index. Diabetes Care 2010;33:e93
14. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387-392 (Pubitemid 11022826)
15. Knowles JW, Assimes TL, Tsao PS, et al. Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. Metabolism 2013;62:548-553
16. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-3578 (Pubitemid 32755946)
17. Kim SH, Abbasi F, Chu JW, et al. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005;54:2447-2452 (Pubitemid 41134274)
18. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 1997;82:1834-1838 (Pubitemid 127495196)
19. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
20. McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006;84:813-821 (Pubitemid 44715663)
21. Reaven GM. What do we learn from measurements of HOMA-IR? Diabetologia 2013;56:1867-1868
22. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2013;50:537-543
23. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-1326 (Pubitemid 34546896)
24. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-922
25. Din FV, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012;142:1504-1515.e3
26. Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol Metab 2013;24:481-487